News | Radiopharmaceuticals and Tracers | May 15, 2017

FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment After Successful Interim Analysis

Study evaluates clinical utility of fluciclovine (18F) PET/CT imaging in men with recurrent prostate cancer following prior treatment

FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis

May 15, 2017 — Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the FALCON clinical study of fluciclovine (18F) PET/CT imaging, based on successful results of a pre-planned interim analysis. The FALCON trial, announced in March 2016, is a U.K.-based, open-label study (NCT02578940) to evaluate the clinical impact of fluciclovine (18F) positron emission tomography/computed tomography (PET/CT) imaging on patient management decisions in men with biochemically recurrent prostate cancer.

In 2016, the U.S. Food and Drug Administration (FDA) approved Axumin (fluciclovine F-18), a novel molecular imaging agent for use in PET imaging in men with suspected prostate cancer recurrence based on elevated blood levels of prostate specific antigen (PSA) following prior treatment.

The primary endpoint of the FALCON study examines the percentage of men who have their management plan changed after a fluciclovine (18F) scan. The single, pre-planned interim analysis of the primary endpoint was performed based on the first 85 evaluable patients. Based on the interim analysis results, recruitment in the trial was to be stopped due to efficacy.

The efficacy and safety of fluciclovine (18F) to impact patient management decisions is currently under clinical investigation. Blue Earth Diagnostics plans to present results of this interim analysis of the FALCON trial at an upcoming medical congress and subsequently publish full results in a peer-reviewed publication.

“The primary aim of the U.K. multi-center FALCON trial of fluciclovine (18F) PET/CT imaging was to assess its clinical impact on treatment decisions in men with recurrent prostate cancer being considered for radical potentially curative treatment,” said Fergus Gleeson, M.D., professor of radiology, University of Oxford, Oxford, U.K., and chief investigator on the study. “Study recruitment has been stopped because of the significant numbers of changes to treatment made following the scan. In addition, we want to evaluate other criteria such as its diagnostic performance and the effect that PSA level may have on the probability of lesion detection by fluciclovine (18F).

“Biochemically recurrent prostate cancer poses an important medical challenge, as it occurs in up to one-third of men who have been previously treated, and current commercially available anatomical imaging techniques are limited in the amount of information they provide,” said Judd Moul, M.D., professor of surgery, urology, at Duke University. “Information provided by an Axumin PET scan provides useful information about the location and extent of suspected recurrent disease and has the potential to provide information to facilitate the appropriate care of men with recurrent prostate cancer.”

Blue Earth Diagnostics also announced that the LOCATE study (“The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment”), has completed patient enrollment earlier than anticipated. The LOCATE trial is a U.S. multi-center study designed to assess the impact on patient management of 18F fluciclovine PET imaging in patients with rising PSA after initial prostate cancer treatment. The clinical utility of 18F fluciclovine PET/CT imaging will be assessed by the change from initial to revised treatment plan.

For more information: www.blueearthdx.com

Related Content

Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
News | PET-CT | February 06, 2019
Technological advancements in positron emission tomography/computed tomography (PET/CT) offer both clinicians and pat
Study Assesses Risk of MRI Exams for Patients With Tattoos
News | Magnetic Resonance Imaging (MRI) | February 01, 2019
A new European study concluded that magnetic resonance imaging (MRI) exams pose little risk for people with tattoos,...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
Southern Asia's First Proton Therapy Center Begins Treatments
News | Proton Therapy | January 28, 2019
IBA (Ion Beam Applications SA) announced the opening of the Apollo Proton Cancer Centre in Chennai, India, and the...
Artificial Intelligence Research Receives RSNA Margulis Award
News | Digital Radiography (DR) | January 28, 2019
The Radiological Society of North America (RSNA) presented its seventh Alexander R. Margulis Award for Scientific...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.